Clinical Trials

Immunoglobulin Light-chain Amyloidosis

NCT05556616 2026-01-29

iinnovate-2

15 enrolled 15 charts

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT02312102 2026-01-16

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

MyeloidOther hematologic neoplasm

22 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT02211755 2025-11-28

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Phase 1 Active not recruiting

28 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

NCT04091126 2025-11-28

DREAMM 9

118 enrolled

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

15 enrolled 91 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

114 enrolled

Lymphoma, Lymphoma, T-Cell

NCT04570631 2025-05-16

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

4 enrolled

Multiple Myeloma

NCT00329589 2025-05-02

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

CNSGynecologicHead & Neck

54 enrolled

Brain Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Central Nervous System Neoplasms

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

240 enrolled 3 FDA

Multiple Myeloma

NCT06900647 2025-04-02

BOCIS

Phase 1 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT04996160 2025-01-24

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Phase 1 Recruiting

22 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03829020 2024-08-22

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT04956302 2024-06-06

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

1 enrolled

Multiple Myeloma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04912427 2024-02-09

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

1 enrolled

Multiple Myeloma

NCT02513186 2024-01-29

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

90 enrolled

Multiple Myeloma

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

15 enrolled

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02514382 2023-08-14

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

14 enrolled

Other hematologic neoplasm

Multiple Myeloma

NCT05982756 2023-08-09

Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

Phase 1 Unknown

40 enrolled

Leukemia, Myeloid, Acute

NCT01728259 2023-05-09

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Immunoglobulin Light-chain Amyloidosis

NCT02484261 2023-03-15

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

Other hematologic neoplasm

10 enrolled

Leukemia

NCT00664898 2022-12-12

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Phase 1 Unknown

60 enrolled

Multiple Myeloma, Recurrence

NCT02613598 2021-12-20

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

15 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01038388 2021-11-03

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT03056599 2021-09-24

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

23 enrolled

Sarcoma

NCT01965353 2021-09-05

PanRVD

21 enrolled

Multiple Myeloma

NCT02481934 2021-08-20

NK-VS-MM

5 enrolled 6 charts

Multiple Myeloma

NCT01794507 2021-08-02

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

66 enrolled

Multiple Myeloma

NCT00858234 2021-04-09

MK-0683-098

9 enrolled 9 charts

Multiple Myeloma

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02100657 2020-10-12

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

39 enrolled 30 charts

Multiple Myeloma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Other hematologic neoplasmPlasma cell

55 enrolled

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT03515200 2020-09-01

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00598169 2020-08-10

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

23 enrolled

Lymphoma

NCT00093704 2020-07-31

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

1 enrolled

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoproliferative Disorders

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01464112 2020-01-22

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma